Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | +48.28% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.15 | N/A | +48.28% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a positive outlook on product demand and innovation. They acknowledged market challenges but remain focused on growth.
Management highlighted the continued demand for their products despite market challenges.
They emphasized their focus on innovation and expanding their customer base.
The earnings report shows that 10X Genomics exceeded expectations on EPS, which likely contributed to the stock's 3.3% increase. The company did not provide revenue figures or future guidance, leaving some uncertainty. However, management's positive comments about demand and innovation suggest a focus on growth moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FIRSTENERGY CORP
Feb 13, 2023